We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

69:HKEXShangri-La Asia Limited Analysis

Data as of 2026-05-21 - not real-time

¥6,556.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

JEOL Ltd. is trading just above its 20‑day simple moving average, aligning with a broader bullish trend despite a bearish MACD histogram and a neutral RSI that suggests limited short‑term momentum. Support around the 6100 level provides a cushion, while the next resistance near 7100 caps upside potential in the near term. The stock exhibits a low beta, indicating modest sensitivity to market swings, yet 30‑day volatility remains elevated, reflecting price swings typical for high‑tech equipment makers. Valuation metrics are compelling: the company’s PE ratio sits well below the industry average, and a dividend yield of over 2% adds income appeal. However, revenue has contracted sharply, highlighting execution risk in a competitive global market. The discounted cash‑flow model appears to price the stock significantly lower than its current level, suggesting possible overvaluation from a pure cash‑flow perspective.
Looking ahead, JEOL’s solid return on equity, sustainable payout ratio, and diversified exposure across scientific, industrial, and medical segments support a longer‑term case for accumulation. The combination of relative valuation attractiveness, dividend sustainability, and sector demand trends outweighs the near‑term technical headwinds, positioning the stock as a favorable buy for investors with a medium to long horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hugging the 20‑day SMA with support intact
  • Neutral RSI and bearish MACD indicating limited upside
  • Stable trading volume and low beta reducing market‑wide shock exposure

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • PE advantage versus industry peers
  • Attractive dividend yield with a comfortable payout ratio
  • Revenue contraction that could pressure earnings growth

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Diversified product portfolio serving high‑growth scientific and medical markets
  • Strong ROE and cash‑flow generation supporting dividend sustainability
  • Relative undervaluation and lower beta offering defensive characteristics

Key Metrics & Analysis

Financial Health

Revenue Growth-17.90%
Profit Margin12.32%
P/E Ratio15.1
ROE15.70%
ROA7.00%
Debt/Equity18.70
P/B Ratio2.3
Op. Cash Flow¥16.0B
Free Cash Flow¥1.9B
Industry P/E38.8

Technical Analysis

TrendBullish
RSI51.7
Support¥6,100.00
Resistance¥7,100.00
MA 20¥6,556.80
MA 50¥6,252.30
MA 200¥5,471.59
MACDBearish
VolumeStable
Fear & Greed Index90.29

Valuation

Fair Value¥753.37
Target Price¥7,000.00
Upside/Downside6.77%
GradeUndervalued
TypeBlend
Dividend Yield2.10%

Risk Assessment

Beta0.71
Volatility52.94%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.